Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management

다국어 초록 (Multilingual Abstract)

Latent autoimmune diabetes in adults (LADA) is a heterogeneous disease characterized by a less intensive autoimmune process and a broad clinical phenotype compared to classical type 1 diabetes mellitus (T1DM), sharing features with both type 2 diabetes mellitus (T2DM) and T1DM. Since patients affected by LADA are initially insulin independent and recognizable only by testing for islet-cell autoantibodies, it could be difficult to identify LADA in clinical setting and a high misdiagnosis rate still remains among patients with T2DM. Ideally, islet-cell autoantibodies screening should be performed in subjects with newly diagnosed T2DM, ensuring a closer monitoring of those resulted positive and avoiding treatment of hyperglycaemia which might increase the rate of β-cells loss. Thus, since the autoimmune process in LADA seems to be slower than in classical T1DM, there is a wider window for new therapeutic interventions that may slow down β-cell failure. This review summarizes the current understanding of LADA, by evaluating data from most recent studies, the actual gaps in diagnosis and management. Finally, we critically highlight and discuss novel findings and future perspectives on the therapeutic approach in LADA.

참고문헌 (Reference)

1 Thunander M, "β-Cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up" 164 : 239-245, 2011

2 Lampasona V, "Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4" 33 : 104-108, 2010

3 Grant SF, "Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes" 38 : 320-323, 2006

4 Turner R, "UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group" 350 : 1288-1293, 1997

5 Buzzetti R, "Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes" 38 : 513-520, 2015

6 D’Alessio DA, "Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes" 94 : 81-88, 2009

7 Bell DS, "The role of C-peptide levels in screening for latent autoimmune diabetes in adults" 11 : 308-311, 2004

8 Roh MO, "The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea" 50 : 129-134, 2013

9 Rawshani A, "The incidence of diabetes among 0-34 year olds in Sweden: new data and better methods" 57 : 1375-1381, 2014

10 Kobayashi T, "Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM" 45 : 622-626, 1996

11 Buzzetti R, "Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA)" 32 : 289-296, 2016

12 Yang Z, "Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study" 83 : 54-60, 2009

13 Zhou Z, "Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA)" 21 : 203-208, 2005

14 Tian L, "Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor" 151 : 3049-3060, 2010

15 Davis AK, "Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes" 38 : 476-481, 2015

16 Qi X, "Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional study" 34 : 66-70, 2011

17 George P, "Potential role of non-insulin adjunct therapy in type 1 diabetes" 30 : 179-188, 2013

18 Zinman B, "Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe" 53 : 3193-3200, 2004

19 Hjort R, "Overweight, obesity and the risk of LADA: results from a Swedish case-control study and the Norwegian HUNT Study" 61 : 1333-1343, 2018

20 Maioli M, "Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults" 163 : 541-549, 2010

21 Hawa MI, "Metabolic syndrome and autoimmune diabetes: action LADA 3" 32 : 160-164, 2009

22 Jones AG, "Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes" 39 : 250-257, 2016

23 Sachan A, "Low prevalence of latent autoimmune diabetes in adults in northern India" 32 : 810-813, 2015

24 Maddaloni E, "Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement" 10 : e0131837-, 2015

25 Britten AC, "Latent autoimmune diabetes in adults in a South Asian population of the U.K" 30 : 3088-3090, 2007

26 Andersen MK, "Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years" 33 : 2062-2064, 2010

27 Fourlanos S, "Latent autoimmune diabetes in adults (LADA) should be less latent" 48 : 2206-2212, 2005

28 Naik RG, "Latent autoimmune diabetes in adults" 94 : 4635-4644, 2009

29 Park Y, "LADA prevalence estimation and insulin dependency during follow-up" 27 : 975-979, 2011

30 Schloot N, "Isohormonal therapy of endocrine autoimmunity" 16 : 289-294, 1995

31 Barinas-Mitchell E, "Islet cell autoimmunity in a triethnic adult population of the Third National Health and Nutrition Examination Survey" 53 : 1293-1302, 2004

32 Brophy S, "Interventions for latent autoimmune diabetes (LADA) in adults" 9 : 2011

33 Tiittanen M, "Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro" 55 : 3446-3454, 2006

34 Argoud GM, "Insulin suppresses its own secretion in vivo" 36 : 959-962, 1987

35 Hernandez M, "Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9" 15 : 1-, 2015

36 Maruyama T, "Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus" 93 : 2115-2121, 2008

37 Haller K, "Insulin gene VNTR, CTLA-4 +49A/G and HLA-DQB1 alleles distinguish latent autoimmune diabetes in adults from type 1 diabetes and from type 2 diabetes group" 69 : 121-127, 2007

38 Bruno G, "Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy" 28 : 2613-2619, 2005

39 Lee SH, "Identifying latent autoimmune diabetes in adults in Korea: the role of C-peptide and metabolic syndrome" 83 : e62-e65, 2009

40 Tiberti C, "Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2" 57 : 1276-1283, 2008

41 Buzzetti R, "High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes" 30 : 932-938, 2007

42 Zampetti S, "High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7)" 171 : 697-704, 2014

43 Radtke MA, "Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trondelag Health (HUNT) study" 32 : 245-250, 2009

44 Bluestone JA, "Genetics, pathogenesis and clinical interventions in type 1 diabetes" 464 : 1293-1300, 2010

45 Sabbah E, "Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes" 23 : 1326-1332, 2000

46 Howson JM, "Genetic analysis of adult-onset autoimmune diabetes" 60 : 2645-2653, 2011

47 Pettus J, "GLP-1 agonists in type 1 diabetes" 149 : 317-323, 2013

48 Zampetti S, "GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6)" 97 : 3759-3765, 2012

49 Desai M, "GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77" 50 : 2052-2060, 2007

50 Zhou Z, "Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study" 62 : 543-550, 2013

51 Fuchtenbusch M, "Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens" 49 : 918-925, 2000

52 Dejgaard TF, "Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial" 4 : 221-232, 2016

53 Jansen A, "Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta-cell rest?" 9 : 341-348, 1996

54 Pozzilli P, "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials" 20 : 1490-1498, 2018

55 Pipi E, "Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus" 5 : 505-510, 2014

56 Zhao Y, "Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study" 99 : E876-E880, 2014

57 Leslie RD, "Diabetes classification: grey zones, sound and smoke: Action LADA 1" 24 : 511-519, 2008

58 Takeda H, "Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study)" 25 : 995-1001, 2002

59 Leslie RD, "Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow" 91 : 1654-1659, 2006

60 Genovese S, "Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes" 154 : 441-447, 2006

61 Park Y, "Clinical heterogeneity of type 1 diabetes (T1D) found in Asia" 33 : e2907-, 2017

62 Tuomi T, "Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies" 48 : 150-157, 1999

63 Yasui J, "Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan" 11 : e0155643-, 2016

64 Yang Z, "Childhood diabetes in China. Enormous variation by place and ethnic group" 21 : 525-529, 1998

65 Johansen OE, "C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study" 37 : e11-e12, 2014

66 Steffes MW, "Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial" 26 : 832-836, 2003

67 Foley JE, "Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naïve patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial" 54 : 1985-1991, 2011

68 Pozzilli P, "Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention" 24 : 1460-1467, 2001

69 Qu HQ, "Association analysis of type 2 diabetes Loci in type 1 diabetes" 57 : 1983-1986, 2008

70 Tuomi T, "Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease" 42 : 359-362, 1993

71 Field SF, "Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects" 50 : 212-213, 2007

72 Desai M, "An association analysis of the HLA gene region in latent autoimmune diabetes in adults" 50 : 68-73, 2007

73 Barker A, "Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study" 16 : 262-267, 2014

74 Buzzetti R, "Adult-onset autoimmune diabetes: current knowledge and implications for management" 13 : 674-686, 2017

75 Hawa MI, "Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7" 36 : 908-913, 2013

76 Mishra R, "A global perspective of latent autoimmune diabetes in adults" 29 : 638-650, 2018

77 Monge L, "A clinically orientated approach increases the efficiency of screening for latent autoimmune diabetes in adults (LADA) in a large clinic-based cohort of patients with diabetes onset over 50 years" 21 : 456-459, 2004

78 Fourlanos S, "A clinical screening tool identifies autoimmune diabetes in adults" 29 : 970-975, 2006

79 American Diabetes Association, "(2) Classification and diagnosis of diabetes" 38 (38): S8-S16, 2015